My Nonprofit Reviews

THANKS !

Your organization has provided co-payment assistance for Novartis GLEEVEC when the use of it was restarted in late September 2022 due to insurance coverage for the Novartis GLEEVEC being approved in a MEDICARE Administrative Law Judge (ALJ) Hearing Appeal.

Your organization had been providing co-payment assistance for Novartis GLEEVEC from January of 2022 till the time in the Spring of 2022 when CIGNA/Express Scripts would not provide insurance coverage for Novartis GLEEVEC.

When CIGNA/Express Scripts denied formulary coverage via a live telephone call in late-March 2022 on a Thursday and the next day, a Friday, via a robocall denied an appeal, WHICH HAD NOT OCCURRED IN REALITY AT THAT TIME, it caused the stopping of the use of Novartis GLEEVEC because CIGNA/Express Scripts would not provide insurance coverage for Novartis GLEEVEC.

In 2019, 2020 and 2021 your organization provided co-payment assistance for Novartis GLEEVEC.

In 2019, 2020 and 2021 CIGNA/Express Scripts approved insurance coverage for a Prior Authorization Approval, which continued the use of the Novartis GLEEVEC, which began in November 2002 in an experimental medical trial, for use against the GIST Cancer which multiple surgeries could not eradicate after the GIST Cancer had been discovered in late-1999.

Prior to 2019, your organization provided co-payment assistance for Novartis GLEEVEC each year that it had been applied for.

Prior to the CIGNA/Express Scripts merger finalization announcement in early 2019, when Express Scripts was a separate entity, it had been approving a Prior Authorization Approval each year so that the Novartis GLEEVEC could be provided under the Express Scripts insurance coverage.